false
0001840877
0001840877
2024-08-12
2024-08-12
0001840877
COCH:ClassCommonStockParValue0.0001PerShareMember
2024-08-12
2024-08-12
0001840877
COCH:RedeemableWarrantsEachWholeWarrantMember
2024-08-12
2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 12, 2024
ENVOY
MEDICAL, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40133 |
|
86-1369123 |
(State
or other jurisdiction
of incorporation) |
|
(Commission File
Number) |
|
(IRS
Employer
Identification No.) |
4875
White Bear Parkway
White Bear Lake, MN |
|
55110 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (877) 900-3277
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Class
A Common Stock, par value $0.0001 per share |
|
COCH |
|
The
Nasdaq Stock Market LLC |
Redeemable
Warrants, each whole Warrant
exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share |
|
COCHW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On
August 12, 2024, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results
for its second fiscal quarter ended June 30, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The
information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that Section. The information in this Item 2.02 shall not be incorporated into any filing pursuant to the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ENVOY MEDICAL,
INC. |
|
|
|
August 12, 2024 |
By: |
/s/
David R. Wells |
|
|
David R. Wells |
|
|
Chief Financial Officer |
2
Exhibit
99.1
Envoy
Medical Reports Second Quarter 2024 Results and Provides Business Update
Company
continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough
fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year
WHITE
BEAR LAKE, Minn., August 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH),
a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results
for the second quarter ended June 30, 2024.
“We
are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading
cochlear implant company,” commented Brent T. Lucas, Envoy Medical’s Chief Executive Officer. “We believe the results
of our Early Feasibility Study justify further study of our breakthrough fully implanted cochlear implant and intend to submit an IDE
application to begin a Pivotal Clinical Trial in the coming months. If our IDE application is approved, we are hopeful that we may begin
enrolling the study before year-end.”
Corporate
Highlights from Q2 2024
Update
on Early Feasibility Study (EFS) at Mayo Clinic
| ● | Each
of the three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester,
MN) have now completed their 18-month follow up visits, continue to be enrolled in the study,
and report using their investigational Acclaim cochlear implant daily. All participants show
improvement in their global quality-of-life scores (via the CIQOL) after 18 months. |
| ● | There
have been neither serious adverse device effects (SADEs) nor unanticipated adverse device
effects (UADEs) as defined reported to date. There have been other adverse events (AEs) and
two revision surgeries – one revision for two participants – to replace the Acclaim
Battery with an updated design. |
| ● | Following
18 months of data collection supporting that the investigational device is capable of delivering
electrical stimulation to the cochlea, the Company believes there is strong justification
to move forward to a pivotal clinical study. |
Update
on System Noise
| ● | The
Company previously communicated that an internal ‘system noise’ hindered the
ability to optimize programming of the investigational Acclaim CI device. It was also noted
that this system noise does not appear to be ‘body noise,’ which is an outcome
that has been reported by other companies attempting fully implanted cochlear implants using
sub-dermal microphones – a different architecture than the Acclaim CI device. |
| ● | The
Company reports that mitigations and updates have been implemented to reduce system noise,
support meaningful improvements to the signal-to-noise ratio, and allow for increased programming
optimization. In addition, it is reasonable that further iterations may be implemented to
facilitate improved performance, as is commonplace as medical devices evolve. |
“AcclaimPlus”
Listening Condition Update
| ● | One
of the outcomes from the EFS was the realization of a potentially meaningful “listening
condition.” The Acclaim’s fundamental architecture is designed to pick up sound
from the ear itself and therefore allows devices – like hearing aids or consumer electronics
– to be used in the ear. Patients that would like to use a similar ‘listening
condition’ in everyday life, may choose an option that allows for such flexibility.
|
| ● | Two
participants chose to wear their hearing aid in the “Acclaim ear” during the
daytime during their participation in the EFS study. At first, this was primarily to mitigate
the system noise. Preliminary data supports that the hearing aid appears to provide additional
gain to the system enabling a better signal to noise ratio, as well as allowing the participants
to enjoy features of the third-party hearing aids such as direct streaming audio and phone
calls. It is possible that some patients will wear a hearing aid in their “Acclaim
ear” to provide the system with more gain and/or to take advantage of certain hearing
aid features. This dataset did not show that the hearing aid provided meaningful acoustic
amplification on its own. Although a small dataset and preliminary, the interim results of
the AcclaimPlus listening condition are encouraging and informative. |
| ● | One
participant chooses to use the Acclaim implant alone at all times. This participant’s
results were also encouraging and informative. |
| ● | The
Company believes that the flexibility patients may have with the fully implanted Acclaim
cochlear implant to use electronic devices and accessories in the implanted ear due to its
design and fundamental architecture could provide interesting opportunities and preferred
features for patients. It could also be an important differentiator for the fully implanted
Acclaim cochlear implant over other competitive devices. |
Timeline
Update
| ● | Envoy
Medical maintains its goal of submitting an application for an Investigational Device Exemption
(IDE) in the next few months. The company is optimistic that it can begin to enroll that
study, should it be approved, by year-end 2024. |
| ● | The
Company will provide more details on study design once approval is granted to begin the study. |
| ● | Assuming
approval, the Company maintains its view that commercialization may be achievable by the
end of 2026. |
Financial
Results for the Quarter Ended June 30, 2024
Revenue
was $68 thousand compared to $63 thousand for the same period in 2023. The increase is attributable to the sale of two Esteem FI-AMEI
units during the period, which offset reduced battery sales due to supply chain issues.
Cost
of goods sold increased by $83 thousand for the same period in 2023. The increase is attributable to manufacturing and materials scrap
for the Esteem FI-AMEI product of $62 thousand, additional contractors for manufacturing technicians and quality inspections of $20 thousand.
and supplies for the newly expanded manufacturing space of $11 thousand with offsets from other costs of $10 thousand.
R&D
expenses increased approximately $438 thousand to $2.6 million for the three months ended June 30, 2024 compared to the same period in
2023. The increase is primarily due to an increase in headcount and contractors in the engineering and clinical departments for the three
months ended June 30, 2024, as the Company increased headcount across its clinical and cochlear departments in preparation for its pivotal
clinical study for the Acclaim CI.
Sales
and marketing expenses increased by approximately $114 thousand to $497 thousand for the three months ended June 30, 2024 as compared
to the same period in 2023. The increase was primarily due to increased market access fees to secure insurance reimbursement
for the Esteem FI-AMEI product, offset by a reduction in headcount in that department.
General
and administrative expenses decreased by $250 thousand to $1.6 million compared to the same period in 2023. The reduction is due
primarily to reduced professional and legal fees related to the closing of the Business Combination in 2023 of $951 thousand, and
was partially offset by increases in personnel-related costs of $198 thousand, directors and officers insurance of $175 thousand,
non-cash stock option expenses of $99 thousand, loss on lease modification of $135 thousand, and other operating costs of $94
thousand, for the three months ended June 30, 2024.
As
of June 30, 2024, the Company had cash and cash equivalents of approximately $1.7 million.
About
the Fully Implanted Acclaim® Cochlear Implant
The
Company believes the fully implanted Acclaim CI will be a first-of-its-kind fully implanted cochlear implant. Envoy Medical’s fully
implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The
Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The
Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified ear surgeon and audiologist.
The
Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION:
The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational
use.
About
the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The
Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed
with moderate to severe sensorineural hearing loss capable of delivering 24/7 hearing capability using the ear’s natural anatomy.
The Esteem FI-AMEI requires no externally worn components and nothing is placed in the ear canal for it to function.* Unlike hearing
aids, you never put it on or take it off.
* | Once activated, the
external Esteem FI-AMEI Personal Programmer is not required for daily use. |
Important
safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional
Information and Where to Find It
Copies
of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking
Statements
This
press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the
United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such
as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,”
“expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions
that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does
not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations
of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital
investments, the availability and benefits of future funding, the Acclaim CI being the first to market fully implanted cochlear implant,
the timing of Envoy Medical’s IDE submission and beginning of its clinical trial, the effect of such clinical trial on the development
of Envoy Medical’s business, the impact of proposed legislation on the hearing health market, reimbursement for the Esteem FI-AMEI
device, and the Envoy Medical business, and future market conditions or economic performance, as well as any information concerning possible
or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s
current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances
that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not
guarantee that the transactions and events described will happen as described (or that they will happen at all). These forward-looking
statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of
Envoy Medical’s Class A Common Stock; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers,
key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the
clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new
products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships
with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components
and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes
in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes
in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual
property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism
and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and
“Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on April
1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions
prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking
statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any
obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information,
data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should
not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor
Contact:
CoreIR
516-222-2560
investorrelations@envoymedical.com
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)
| |
June 30, 2024 | | |
December 31, 2023 | |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash | |
$ | 1,746 | | |
$ | 4,218 | |
Accounts receivable | |
| 174 | | |
| 70 | |
Other receivables | |
| 28 | | |
| 176 | |
Inventories | |
| 1,582 | | |
| 1,404 | |
Prepaid expenses and other current assets | |
| 1,466 | | |
| 957 | |
Total current assets | |
| 4,996 | | |
| 6,825 | |
Property and equipment, net | |
| 632 | | |
| 351 | |
Operating lease right-of-use assets (related party) | |
| 1,109 | | |
| 464 | |
Total assets | |
$ | 6,737 | | |
$ | 7,640 | |
| |
| | | |
| | |
Liabilities and stockholders’ deficit | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,589 | | |
$ | 1,554 | |
Accrued expenses | |
| 6,004 | | |
| 4,613 | |
Product warranty liability, current portion | |
| 290 | | |
| 311 | |
Operating lease liabilities (related party), current portion | |
| 175 | | |
| 158 | |
Total current liabilities | |
| 8,058 | | |
| 6,636 | |
Term loan payable (related party) | |
| 7,292 | | |
| — | |
Product warranty liability, net of current portion | |
| 1,923 | | |
| 1,923 | |
Operating lease liabilities (related party), net of current portion | |
| 1,121 | | |
| 404 | |
Publicly traded warrant liability | |
| 708 | | |
| 332 | |
Forward purchase agreement put option liability | |
| — | | |
| 103 | |
Forward purchase agreement warrant liability | |
| 22 | | |
| 4 | |
Total liabilities | |
| 19,124 | | |
| 9,402 | |
| |
| | | |
| | |
Commitments and contingencies (see Note 14) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ deficit: | |
| | | |
| | |
Series A Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 4,500,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | |
| — | | |
| — | |
Class A Common Stock, $0.0001 par value; 400,000,000 shares authorized as of June 30, 2024 and December 31, 2023 respectively; 19,599,982 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | |
| 2 | | |
| 2 | |
Additional paid-in capital | |
| 257,920 | | |
| 255,596 | |
Accumulated deficit | |
| (270,189 | ) | |
| (257,242 | ) |
Accumulated other comprehensive loss | |
| (120 | ) | |
| (118 | ) |
Total stockholders’ deficit | |
| (12,387 | ) | |
| (1,762 | ) |
Total liabilities and stockholders’ deficit | |
$ | 6,737 | | |
$ | 7,640 | |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Net revenues | |
$ | 68 | | |
$ | 63 | | |
$ | 127 | | |
$ | 141 | |
Cost and operating expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of goods sold | |
| 245 | | |
| 162 | | |
| 398 | | |
| 337 | |
Research and development | |
| 2,591 | | |
| 2,153 | | |
| 4,951 | | |
| 4,080 | |
Sales and marketing | |
| 497 | | |
| 383 | | |
| 822 | | |
| 754 | |
General and administrative | |
| 1,595 | | |
| 1,845 | | |
| 3,714 | | |
| 3,221 | |
Total costs and operating expenses | |
| 4,928 | | |
| 4,543 | | |
| 9,885 | | |
| 8,392 | |
Operating loss | |
| (4,860 | ) | |
| (4,480 | ) | |
| (9,758 | ) | |
| (8,251 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Loss from changes in fair value of convertible notes payable (related party) | |
| — | | |
| (8,766 | ) | |
| — | | |
| (18,143 | ) |
Change in fair value of forward purchase agreement put option liability | |
| — | | |
| — | | |
| 103 | | |
| — | |
Change in fair value of forward purchase agreement warrant liability | |
| 244 | | |
| — | | |
| (18 | ) | |
| — | |
Change in fair value of publicly traded warrant liability | |
| 801 | | |
| — | | |
| (376 | ) | |
| — | |
Interest expense, related party | |
| (132 | ) | |
| — | | |
| (168 | ) | |
| — | |
Other expense | |
| — | | |
| — | | |
| — | | |
| (105 | ) |
Total other income (expense), net | |
| 913 | | |
| (8,766 | ) | |
| (459 | ) | |
| (18,248 | ) |
Net loss | |
$ | (3,947 | ) | |
$ | (13,246 | ) | |
$ | (10,217 | ) | |
$ | (26,499 | ) |
| |
| | | |
| | | |
| | | |
| | |
Accrued preferred stock dividend | |
$ | (1,365 | ) | |
$ | — | | |
$ | (2,730 | ) | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common stockholders, basic and diluted | |
$ | (5,312 | ) | |
$ | (13,246 | ) | |
$ | (12,947 | ) | |
$ | (26,499 | ) |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.27 | ) | |
$ | (1.31 | ) | |
$ | (0.66 | ) | |
$ | (2.62 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average common stock outstanding, basic and diluted | |
| 19,599,982 | | |
| 10,122,581 | | |
| 19,599,982 | | |
| 10,122,581 | |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive loss: | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation adjustment | |
| (1 | ) | |
| (1 | ) | |
| (2 | ) | |
| — | |
Other comprehensive loss | |
| (1 | ) | |
| (1 | ) | |
| (2 | ) | |
| — | |
Comprehensive loss | |
$ | (3,948 | ) | |
$ | (13,247 | ) | |
$ | (10,219 | ) | |
$ | (26,499 | ) |
The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)
| |
Six Months Ended June 30, | |
| |
2024 | | |
2023 | |
Cash flows from operating activities | |
| | |
| |
Net loss | |
$ | (10,217 | ) | |
$ | (26,499 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation | |
| 76 | | |
| 56 | |
Stock-based compensation | |
| 265 | | |
| — | |
Change in fair value of convertible notes payable (related party) | |
| — | | |
| 18,143 | |
Change in fair value of warrant liability (related party) | |
| — | | |
| 104 | |
Change in fair value of publicly traded warrant liability | |
| 376 | | |
| — | |
Change in fair value of forward purchase agreement warrant liability | |
| 18 | | |
| — | |
Change in fair value of forward purchase agreement put option liability | |
| (103 | ) | |
| — | |
Change in operating lease right-of-use assets (related party) | |
| (645 | ) | |
| 52 | |
Change in inventory reserve | |
| 262 | | |
| (17 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable, net | |
| (104 | ) | |
| (14 | ) |
Other receivables | |
| 148 | | |
| — | |
Inventories | |
| (440 | ) | |
| 6 | |
Prepaid expenses and other current assets | |
| 33 | | |
| (165 | ) |
Accounts payable | |
| 35 | | |
| 1,357 | |
Operating lease liabilities (related party) | |
| 734 | | |
| (75 | ) |
Accrued expenses | |
| (1,171 | ) | |
| 139 | |
Product warranty liability | |
| (21 | ) | |
| (132 | ) |
Net cash used in operating activities | |
$ | (10,754 | ) | |
$ | (7,045 | ) |
| |
| | | |
| | |
Cash flows from investing activities | |
| | | |
| | |
Purchases of property and equipment | |
| (357 | ) | |
| (70 | ) |
Deposit on equipment not yet placed in service | |
| (542 | ) | |
| — | |
Net cash used in investing activities | |
$ | (899 | ) | |
$ | (70 | ) |
| |
| | | |
| | |
Cash flows from financing activities | |
| | | |
| | |
Proceeds from the issuance of convertible notes payable (related party) | |
| — | | |
| 7,000 | |
Proceeds from the issuance of term loan (related party) | |
| 7,500 | | |
| — | |
Proceeds from the sale of common stock associated with the forward purchase agreement, net of transaction costs | |
| 1,683 | | |
| — | |
Net cash provided by financing activities | |
$ | 9,183 | | |
$ | 7,000 | |
| |
| | | |
| | |
Effect of exchange rate changes on cash | |
| (2 | ) | |
| — | |
Net decrease in cash | |
| (2,472 | ) | |
| (115 | ) |
Cash, beginning of period | |
| 4,218 | | |
| 183 | |
Cash, end of period | |
$ | 1,746 | | |
$ | 68 | |
| |
| | | |
| | |
Supplemental disclosures of cash flow information | |
| | | |
| | |
Cash paid for interest | |
$ | — | | |
$ | — | |
Cash paid for income taxes | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
Non-cash investing and financing activities | |
| | | |
| | |
Deemed capital contribution from related party | |
$ | — | | |
$ | 2,988 | |
Dividends on Series A Preferred Shares | |
$ | 2,730 | | |
$ | — | |
Warrants issued with term note | |
$ | 376 | | |
$ | — | |
The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.
8
v3.24.2.u1
Cover
|
Aug. 12, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 12, 2024
|
Entity File Number |
001-40133
|
Entity Registrant Name |
ENVOY
MEDICAL, INC.
|
Entity Central Index Key |
0001840877
|
Entity Tax Identification Number |
86-1369123
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
4875
White Bear Parkway
|
Entity Address, City or Town |
White Bear Lake
|
Entity Address, State or Province |
MN
|
Entity Address, Postal Zip Code |
55110
|
City Area Code |
(877)
|
Local Phone Number |
900-3277
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Class A Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Class
A Common Stock, par value $0.0001 per share
|
Trading Symbol |
COCH
|
Security Exchange Name |
NASDAQ
|
Redeemable Warrants, each whole Warrant |
|
Title of 12(b) Security |
Redeemable
Warrants, each whole Warrant
|
Trading Symbol |
COCHW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=COCH_ClassCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=COCH_RedeemableWarrantsEachWholeWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Envoy Medical (NASDAQ:COCH)
過去 株価チャート
から 7 2024 まで 8 2024
Envoy Medical (NASDAQ:COCH)
過去 株価チャート
から 8 2023 まで 8 2024